Free Trial

Viridian Therapeutics Q3 2023 Earnings Report

Viridian Therapeutics logo
$18.13 +1.07 (+6.27%)
As of 04:00 PM Eastern

Viridian Therapeutics EPS Results

Actual EPS
-$1.09
Consensus EPS
-$1.22
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Viridian Therapeutics Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
$0.28 million
Beat/Miss
Missed by -$210.00 thousand
YoY Revenue Growth
N/A

Viridian Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Viridian Therapeutics Earnings Headlines

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
See More Viridian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email.

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN), a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

View Viridian Therapeutics Profile

More Earnings Resources from MarketBeat